Ecolab Inc. — Q2 2021 Form 10-Q
Business context and reporting period. The filing covers the quarter and six months ended June 30, 2021. Ecolab provides cleaning, sanitation, water-treatment and related services across Global Industrial, Global Institutional & Specialty, Global Healthcare & Life Sciences, and Other. The 2020 comparative results reflect the ChampionX separation as discontinued operations; accordingly, continuing-operations comparisons are more informative than total net income comparisons.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Net sales | $3,162.7m | $2,685.7m | $6,047.7m | $5,706.3m |
| Operating income | $447.8m | $192.0m | $745.1m | $568.2m |
| Net income attributable to Ecolab from continuing operations | $310.8m | $128.9m | $504.4m | $420.9m |
| Diluted continuing-operations EPS | $1.08 | $0.44 | $1.75 | $1.44 |
| Cash from operating activities | — | $798.3m | $640.2m |
- Reported Q2 sales rose 18%; fixed-currency sales rose 13% and acquisition-adjusted fixed-currency sales rose 12%. For the first half, reported sales increased 6% and fixed-currency sales increased 3%.
- Q2 reported gross margin was 41.7%, versus 39.1%; adjusted gross margin was 41.8%, versus 40.1%. Q2 reported operating margin was 14.2%, versus 7.1%; adjusted operating margin was 14.8%, versus 10.7%.
- Adjusted diluted continuing-operations EPS was $1.22 in Q2, up 88%, and $2.03 for the first half, up 24%. These are non-GAAP measures excluding special items and discrete tax items.
- Q2 sales growth was particularly strong in Institutional & Specialty, up 34% at fixed currency, reflecting market recovery, wins and pricing. Industrial sales increased 4%, while Healthcare & Life Sciences declined 6% against elevated COVID-related demand in the prior year. Other grew 23%.
- Q2 Industrial operating income declined 9% at fixed currency, with margin pressure from higher delivered product costs, Texas freeze impacts and variable compensation. Institutional & Specialty returned to positive operating income from a loss in the prior-year quarter; Healthcare & Life Sciences income declined 30% at fixed currency.
- First-half operating cash flow increased $158m year over year. The company cited higher continuing-operations earnings excluding disposal and impairment charges, lower annual bonus payments and favorable deferred-tax movements, partly offset by unfavorable working-capital changes. Capital expenditures were $245.6m; cash used in investing activities was $347.8m.
- At June 30, cash was $1,402.4m, total current assets $5,487.4m and current liabilities $2,880.3m. Total debt was approximately $6.7bn and net debt $5,323.8m; the company reported net debt/EBITDA of 2.2x, versus 2.4x in the comparison shown in the filing.
- First-half dividends paid were $286.6m and share repurchases were $70.6m. The quarterly dividend declared was $0.48 per share.
Material changes, outlook and notable items
- Prior-year comparisons were affected by the 2020 ChampionX separation and the resulting discontinued-operations loss of $2,163.9m for Q2 2020 and $2,172.5m for the first half. Ecolab reported positive continuing-operations earnings in 2021.
- Q2 2021 special charges and gains totaled $40.9m, including $21.3m affecting operating income and a $19.6m U.S. pension lump-sum settlement expense. The comparable Q2 2020 total was $97.1m, including $44.7m of disposal and impairment charges. First-half totals were $73.3m and $122.1m, respectively.
- Management expects continued strong year-over-year performance in the second half of 2021, assuming recovery continues in the U.S. and Europe reopens as forecast. It cited pricing actions intended to address inflation and rising delivered product costs. The filing does not provide a specific full-year revenue or EPS forecast.
- Restructuring plans remain in progress. The Institutional Plan has anticipated total costs of $80m and targeted annual savings of approximately $50m by 2024; Accelerate 2020 has anticipated costs of $255m and targeted annual savings of $315m by 2022. Actual costs and savings may vary.
- COVID-19 conditions, uneven regional reopening and vaccination, potential variants, supply shortages and inflation remain risks. Other disclosed risks include raw-material cost or availability, foreign-exchange and international-market exposure, cybersecurity and ERP implementation, litigation and environmental matters, and tax or indemnification liabilities related to the ChampionX separation.
- Ecolab reported compliance with debt covenants and no commercial paper or revolving-credit borrowings at quarter-end. Its $2.0bn revolving facility was extended to April 2026. A U.S. healthcare business was acquired after quarter-end for approximately $120m; management said it was not material.
- The interim financial statements received a review, not an audit, by the independent registered public accounting firm. Management stated disclosure controls were effective as of June 30, 2021.
Important facts for investors to verify
- Whether Institutional and other customer-market recovery persists, and how much reported growth reflects durable volume, pricing, currency translation or comparison effects.
- Whether pricing offsets inflation, Texas freeze-related and other delivered-cost pressures without materially affecting demand or margins.
- Progress against restructuring cost, timing and savings targets, and the associated cash expenditures.
- Cash conversion and working-capital trends, capital spending, dividend and repurchase requirements, and the sustainability of leverage at the reported 2.2x net debt/EBITDA.
- Potential effects of COVID-19 developments, supply constraints, legal and environmental contingencies, and ChampionX-related tax or indemnification obligations.